Tyra biosciences announces fireside chat on achondroplasia and growth disorders at ubs biotech management live call series

Carlsbad, calif. , july 21, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today that company management will participate in a virtual fireside chat as part of the ubs biotech management live call series on july 25, 2025.
TYRA Ratings Summary
TYRA Quant Ranking